Cargando…

Cardiorenal benefits of early versus late cyclosporine to sirolimus conversion in a rat model

OBJECTIVE: To compare the cardiorenal effects of early versus late cyclosporine (CsA) to sirolimus (SRL) conversion, using a novel animal model that mimics these protocols used in the clinical practice, and focusing on blood pressure, heart rate (HR), biochemical data and heart and kidney lipid pero...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sereno, José, Romão, Ana M., Parada, Belmiro, Lopes, Patrícia, Carvalho, Eugénia, Teixeira, Frederico, Reis, Flávio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2012
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356955/ https://www.ncbi.nlm.nih.gov/pubmed/22629089 http://dx.doi.org/10.4103/0976-500X.95513

Ejemplares similares

Conversion to Sirolimus Ameliorates Cyclosporine-Induced Nephropathy in the Rat: Focus on Serum, Urine, Gene, and Protein Renal Expression Biomarkers
por: Sereno, José, et al.
Publicado: (2014)

Comparison of Early and Late Conversion of Sirolimus in Experimental Model of Chronic Cyclosporine Nephropathy
por: Kim, Jin Young, et al.
Publicado: (2012)

Transition from Cyclosporine-Induced Renal Dysfunction to Nephrotoxicity in an in Vivo Rat Model
por: Sereno, José, et al.
Publicado: (2014)

Budget impact analysis of conversion from cyclosporine to sirolimus as immunosuppressive medication in renal transplantation therapy
por: Foroutan, Naghmeh, et al.
Publicado: (2013)

Omega-3 Fatty Acids Inhibit Tumor Growth in a Rat Model of Bladder Cancer
por: Parada, Belmiro, et al.
Publicado: (2013)

The combined use of sirolimus and cyclosporin in the management of refractory minimal change nephropathy: ‘a novel use of sirolimus’
por: Davison, Rachel, et al.
Publicado: (2009)

Reduced Prevalence of Dementia in Patients Prescribed Tacrolimus, Sirolimus, or Cyclosporine
por: Silva, Jacqueline D., et al.
Publicado: (2023)

Chemopreventive Efficacy of Atorvastatin against Nitrosamine-Induced Rat Bladder Cancer: Antioxidant, Anti-Proliferative and Anti-Inflammatory Properties
por: Parada, Belmiro, et al.
Publicado: (2012)

Tremor Induced by Cyclosporine, Tacrolimus, Sirolimus, or Everolimus: A Review of the Literature
por: Wagle Shukla, Aparna, et al.
Publicado: (2023)

Oral mucositis after tacrolimus/sirolimus or cyclosporine/methotrexate as graft‐versus‐host disease prophylaxis
por: Garming Legert, Karin, et al.
Publicado: (2020)

Everolimus and Sirolimus in Combination with Cyclosporine Have Different Effects on Renal Metabolism in the Rat
por: Bohra, Rahul, et al.
Publicado: (2012)

Utilization of Mycophenolic Acid, Azathioprine, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus: Multinational Study
por: Sahman, Majda, et al.
Publicado: (2021)

Sirolimus Enhances Cyclosporine A-Induced Cytotoxicity in Human Renal Glomerular Mesangial Cells
por: O'Connell, Séin, et al.
Publicado: (2012)

In Vitro Interaction between Isavuconazole and Tacrolimus, Cyclosporin A, or Sirolimus against Aspergillus Species
por: Schwarz, Patrick, et al.
Publicado: (2020)

Cardiorenal benefits of finerenone: protecting kidney and heart
por: González-Juanatey, José R., et al.
Publicado: (2023)

Safety and immunologic benefits of conversion to sirolimus in kidney transplant recipients with long-term exposure to calcineurin inhibitors
por: Yu, Ji Hyun, et al.
Publicado: (2016)

Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat)
por: Ferreira, Liliana, et al.
Publicado: (2010)

Preventive but Not Curative Efficacy of Celecoxib on Bladder Carcinogenesis in a Rat Model
por: Sereno, José, et al.
Publicado: (2010)

Sirolimus therapy following early cyclosporine withdrawal in transplant patients: mechanisms of action and clinical results
por: Thervet, Eric
Publicado: (2006)

Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft‐versus‐host disease prophylaxis
por: Hernani, Rafael, et al.
Publicado: (2021)

Sirolimus versus cyclosporine A in patients with primary acquired pure red cell aplasia: a prospective cohort study
por: Yang, Yuan, et al.
Publicado: (2023)

Inhibition of Bladder Tumor Growth by Chitooligosaccharides in an Experimental Carcinogenesis Model
por: Fernandes, João C., et al.
Publicado: (2012)

Simultaneous Determination of Cyclosporine A, Tacrolimus, Sirolimus, and Everolimus in Whole-Blood Samples by LC-MS/MS
por: Karapirli, Mustafa, et al.
Publicado: (2012)

Application of Allogeneic Bone Marrow Cells in View of Residual Alloreactivity: Sirolimus but Not Cyclosporine Evolves Tolerogenic Properties
por: Timrott, Kai, et al.
Publicado: (2015)

Sirolimus and tacrolimus rather than cyclosporine A cause bone loss in healthy adult male rats
por: Rubert, Mercedes, et al.
Publicado: (2015)

The SMART trial; does it make us wiser in choosing between sirolimus in preference to cyclosporine – A postrenal transplant?
por: Mishra, Ankit
Publicado: (2021)

Sirolimus-induced interstitial lung disease and resolution after conversion to everolimus
por: Alkhunaizi, Ahmed M., et al.
Publicado: (2020)

Pharmacokinetic Assessment of Drug‐Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults
por: Groll, Andreas H., et al.
Publicado: (2016)

Late Thrombosis of Sirolimus-Eluting Stent: A Multifactorial Problem
por: Kranjec, Igor, et al.
Publicado: (2009)

The Cardiorenal Syndrome
por: Rosner, Mitchell H., et al.
Publicado: (2011)

Cardiorenal syndrome
por: Schetz, Miet
Publicado: (2009)

Cardiorenal syndrome
por: Ye, Wen Qing Wendy, et al.
Publicado: (2023)

Are the Cardiorenal Benefits of SGLT2 Inhibitors Due to Inhibition of the Sympathetic Nervous System?
por: Verma, Subodh
Publicado: (2020)

Sodium-Glucose Cotransporter-2 Inhibition Benefits in Cardiorenal Risk in Men and Women
por: Pruett, Jacob E, et al.
Publicado: (2022)

The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class?
por: Godinho, Ricardo, et al.
Publicado: (2015)

Differential Effects of Acute (Extenuating) and Chronic (Training) Exercise on Inflammation and Oxidative Stress Status in an Animal Model of Type 2 Diabetes Mellitus
por: Teixeira de Lemos, Edite, et al.
Publicado: (2011)

Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotype
por: Carroll, Robert P., et al.
Publicado: (2013)

Cardiorenal Syndromes and Sepsis
por: Chelazzi, C., et al.
Publicado: (2011)

Biomarkers in Cardiorenal Syndromes
por: Fu, Shihui, et al.
Publicado: (2018)

Biomarkers in Cardiorenal Syndrome
por: Goffredo, Giovanni, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_buup0mni2b14dcocaqleojhgck